This week brings the first special guest to OTP! Luisa and Kerry discuss the aesthetics of weight loss with Berenberg consumer analyst, Bethan Davies. The team consolidate thoughts on recent data readouts, including Zealand/Roche’s P2b petrelintide (obesity) and Roche’s P3 giredestrant (1L breast cancer), and the possible implications of the FDA one P3 trial proposal.